Cycle on Oct 5, 2026

I'll start this research cycle by reviewing open threads and existing notes, then pull fresh evidence.

I have the full picture of threads and notes. Several watches are due: the Section 232 pharma tariff full implementation (Sept 29 fire date, now passed), the Census construction spending release (expected Oct 1), and the SK Hynix–Intel Ohio deal status. Let me check each with fresh searches.

Three key developments to verify: (1) Section 232 pharma duties went fully live Sept 29 with new specialty carve-outs, (2) the August Census construction release landed Oct 1, (3) SK Hynix–Intel Ohio still unconfirmed. Let me fetch the primary sources.

Primary sources confirmed. Now let me check for pharma onshoring-plan uptake, the latest ISM manufacturing data, and pull market views (macro backdrop matters given the Treasury-yield surge mentioned; INTC after its September rally).

Strong results. The ISM data shows a manufacturing expansion with a sharp price squeeze, and the macro view shows a 5.24% 10-year Treasury — a real financing headwind for capex. Let me verify the Genentech groundbreaking (relevant to the pharma watch) and check the Bayer Ohio claim, plus scan for any other major reshoring announcements this week.

Two major pharma reshoring data points confirmed: Bayer's $2.2B New Albany, Ohio plant (announced Oct 2, three days after the tariff went fully live) and Genentech's $750M Hillsboro groundbreaking (Sept 28). There's also a Bloomberg report that TSMC is weighing a Texas fab. Let me verify the TSMC item and get the Forbes reshoring scorecard for the announced-vs-groundbreaking divergence.

TSMC's Texas deliberation is confirmed by Bloomberg (Oct 1). Let me pull the TSM market view to ground the semiconductor side, then write up the findings.

All evidence is in hand. Now I'll write the findings: updates to the pharma tariff note (implementation live + Bayer/Genentech), the construction spending note (August data), the Intel/TSMC note (market views + TSMC Texas), and a new note on the ISM/cost-squeeze picture.

Two notes saved. The third call was malformed — let me write the ISM/cost-squeeze note and the Intel/TSMC update now.

All four findings are saved. Now I'll record the two fired watches and register the new forward-looking triggers this cycle surfaced.

The cycle is complete. Here's what this research cycle found and persisted: **Four findings written:** 1. **[[pharma-api-reshoring-tariff-deadlines]]** (updated) — Section 232 went fully live Sept 29 as scheduled, and the operative rate ladder is now public: 100% default on patented drugs, 15% for certain countries, 0% UK, **20% with a qualifying onshoring plan, 0% with an onshoring agreement (expires Jan 20, 2029)**, plus specialty zero-rate carve-outs (rare disease, fertility, cell/gene therapy, animal health). The pledge machine kept running: **Bayer announced a $2.2B New Albany, Ohio plant on Oct 2** — three days after the deadline — and **Genentech broke ground on $750M in Hillsboro Sept 28** (though under Roche's pre-existing tariff exemption, with "format capacity with nothing yet assigned to it"). 2. **[[us-manufacturing-construction-spending-plateau]]** (updated) — The August C30 (Oct 1) shows manufacturing construction rose MoM **for the first time since January** ($170.7B SAAR) but is still **-19.2% YoY / -21.8% YTD**. Data centers jumped +7.5% MoM, +73% YoY, +149% annualized since March — ABC's Basu: momentum "will likely remain confined to the data center and power categories." 3. **[[ism-manufacturing-cost-squeeze]]** (new) — ISM at 54.5 (nine straight months of expansion, new orders accelerating) but **prices paid surged to 77.9**, the highest since the Iran war began, with the 10-year at 5.24% and the Fed at 3.75%. The demand recovery is real; the margin and financing squeeze is the new story. 4. **[[chips-act-restructuring-intel-equity-and-tsmc-acceleration]]** (updated) — INTC at $119.33 (+30.2%/month, $630.8B cap) on the unconfirmed SK Hynix Ohio memory option while TTM net margin is -19.8%; TSMC is weighing a **Texas campus ($20B+ per fab) beyond its $265B Arizona bet**, contingent on the 35% tax-credit extension. Forbes' scorecard quantifies the announced-vs-built gap: **$11T announced vs $232B actual FDI** — "reshoring's biggest winner was not in the White House; it was the purchase order." **Watch management:** resolved the Section 232 implementation watch (fired on schedule); logged the Census monthly release (ongoing); registered two new triggers — TSMC's Texas decision and Intel's late-October Q3 earnings.

The research cycle is complete. The topic's living findings now reflect the first week of October 2026: the pharma tariff regime fully in force with its onshoring rate ladder, the factory-shell decline stabilizing while data centers carry construction, a manufacturing expansion colliding with war-level input costs and 5%+ long rates, and the semiconductor trade bifurcating between revenue-converters (TSMC) and option-pricers (Intel). Next cycle's highest-value targets: Thermo Fisher/Danaher Q3 earnings for the pharma equipment-order test, TSMC's October 15 results, and Intel's late-October print.